Statin research in critical illness: hampered by poor trial design?

Nursing and Health Professions

• C Reactive Protein 50%
• Cardiopulmonary Bypass 50%
• Critical Illness 100%
• Disease Marker 50%
• Heart Surgery 50%
• Inflammation 100%
• Intensive Care 50%
• Interleukin 6 50%
• Meta Analysis 50%
• Placebo 50%
• Statin (Protein) 100%
• Statins therapy 100%
• Systematic Review 50%
• Tumor Necrosis Factor 50%

Medicine and Dentistry

• C Reactive Protein 33%
• Cardiopulmonary Bypass 33%
• Critical Illness 100%
• Disease Marker 33%
• Heart Surgery 33%
• Intensive Care 33%
• Interleukin 6 33%
• Meta-Analysis 33%
• Placebo 33%
• Randomized Controlled Trial 33%
• Serositis 33%
• Statin 100%
• Systematic Review 33%
• Tumor Necrosis Factor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• C Reactive Protein 33%
• Critical Illness 100%
• Disease Marker 33%
• Inflammation 66%
• Interleukin 6 33%
• Placebo 33%
• Randomized Controlled Trial 33%
• Statin (Protein) 100%
• Tumor Necrosis Factor 33%